Intensive care medicine research agenda on invasive fungal infection in critically ill patients

Matteo Bassetti, Jose Garnacho-Montero, Thierry Calandra, Bartjan Kullberg, George Dimopoulos, Elie Azoulay, Arunaloke Chakrabarti, Daniel H Kett, Cristobal Leon, Luis Ostrosky-Zeichner, Maurizio Sanguinetti, Jean Francois Timsit, Malcom D. Richardson, Andrew Shorr, Oliver A. Cornely

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting. Methods: A systematic review of the medical literature taking account of national and international guidelines and expert opinion. Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80% of IFIs are due to Candida spp. and 0.3–19% to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [β-1 → 3-d-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment. Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalIntensive Care Medicine
DOIs
StateAccepted/In press - Mar 2 2017

Fingerprint

Critical Care
Candida
Critical Illness
Medicine
Aspergillus
Research
Aspergillosis
Glucans
Mortality
Candidiasis
Expert Testimony
Standard of Care
Secondary Prevention
Candida albicans
Human Influenza
Uncertainty
Disease Outbreaks
Sepsis
Pharmacokinetics
Biomarkers

Keywords

  • Antifungals
  • Aspergillus
  • Beta-d-glucan
  • Candida
  • Echinocandins
  • Fluconazole

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., ... Cornely, O. A. (Accepted/In press). Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Medicine, 1-14. https://doi.org/10.1007/s00134-017-4731-2

Intensive care medicine research agenda on invasive fungal infection in critically ill patients. / Bassetti, Matteo; Garnacho-Montero, Jose; Calandra, Thierry; Kullberg, Bartjan; Dimopoulos, George; Azoulay, Elie; Chakrabarti, Arunaloke; Kett, Daniel H; Leon, Cristobal; Ostrosky-Zeichner, Luis; Sanguinetti, Maurizio; Timsit, Jean Francois; Richardson, Malcom D.; Shorr, Andrew; Cornely, Oliver A.

In: Intensive Care Medicine, 02.03.2017, p. 1-14.

Research output: Contribution to journalArticle

Bassetti, M, Garnacho-Montero, J, Calandra, T, Kullberg, B, Dimopoulos, G, Azoulay, E, Chakrabarti, A, Kett, DH, Leon, C, Ostrosky-Zeichner, L, Sanguinetti, M, Timsit, JF, Richardson, MD, Shorr, A & Cornely, OA 2017, 'Intensive care medicine research agenda on invasive fungal infection in critically ill patients', Intensive Care Medicine, pp. 1-14. https://doi.org/10.1007/s00134-017-4731-2
Bassetti M, Garnacho-Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Medicine. 2017 Mar 2;1-14. https://doi.org/10.1007/s00134-017-4731-2
Bassetti, Matteo ; Garnacho-Montero, Jose ; Calandra, Thierry ; Kullberg, Bartjan ; Dimopoulos, George ; Azoulay, Elie ; Chakrabarti, Arunaloke ; Kett, Daniel H ; Leon, Cristobal ; Ostrosky-Zeichner, Luis ; Sanguinetti, Maurizio ; Timsit, Jean Francois ; Richardson, Malcom D. ; Shorr, Andrew ; Cornely, Oliver A. / Intensive care medicine research agenda on invasive fungal infection in critically ill patients. In: Intensive Care Medicine. 2017 ; pp. 1-14.
@article{4c569446665a493f9606a62ae1110370,
title = "Intensive care medicine research agenda on invasive fungal infection in critically ill patients",
abstract = "Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting. Methods: A systematic review of the medical literature taking account of national and international guidelines and expert opinion. Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80{\%} of IFIs are due to Candida spp. and 0.3–19{\%} to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [β-1 → 3-d-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment. Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.",
keywords = "Antifungals, Aspergillus, Beta-d-glucan, Candida, Echinocandins, Fluconazole",
author = "Matteo Bassetti and Jose Garnacho-Montero and Thierry Calandra and Bartjan Kullberg and George Dimopoulos and Elie Azoulay and Arunaloke Chakrabarti and Kett, {Daniel H} and Cristobal Leon and Luis Ostrosky-Zeichner and Maurizio Sanguinetti and Timsit, {Jean Francois} and Richardson, {Malcom D.} and Andrew Shorr and Cornely, {Oliver A.}",
year = "2017",
month = "3",
day = "2",
doi = "10.1007/s00134-017-4731-2",
language = "English (US)",
pages = "1--14",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Intensive care medicine research agenda on invasive fungal infection in critically ill patients

AU - Bassetti, Matteo

AU - Garnacho-Montero, Jose

AU - Calandra, Thierry

AU - Kullberg, Bartjan

AU - Dimopoulos, George

AU - Azoulay, Elie

AU - Chakrabarti, Arunaloke

AU - Kett, Daniel H

AU - Leon, Cristobal

AU - Ostrosky-Zeichner, Luis

AU - Sanguinetti, Maurizio

AU - Timsit, Jean Francois

AU - Richardson, Malcom D.

AU - Shorr, Andrew

AU - Cornely, Oliver A.

PY - 2017/3/2

Y1 - 2017/3/2

N2 - Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting. Methods: A systematic review of the medical literature taking account of national and international guidelines and expert opinion. Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80% of IFIs are due to Candida spp. and 0.3–19% to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [β-1 → 3-d-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment. Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.

AB - Purpose: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting. Methods: A systematic review of the medical literature taking account of national and international guidelines and expert opinion. Results: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80% of IFIs are due to Candida spp. and 0.3–19% to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [β-1 → 3-d-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment. Conclusions: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.

KW - Antifungals

KW - Aspergillus

KW - Beta-d-glucan

KW - Candida

KW - Echinocandins

KW - Fluconazole

UR - http://www.scopus.com/inward/record.url?scp=85014094927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014094927&partnerID=8YFLogxK

U2 - 10.1007/s00134-017-4731-2

DO - 10.1007/s00134-017-4731-2

M3 - Article

C2 - 28255613

AN - SCOPUS:85014094927

SP - 1

EP - 14

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

ER -